Drugs / Voriconazole
Voriconazole
also known as
vfend · NSC-759888 · UK-109,496 · Vaway FC Tablets · VFEND FC Tablets · VFEND I.V. · VFend(R) · Vori · +4 more
Small molecule targets CYP2B6, CYP2C19, CYP3A4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | VFEND | — | 2004-12-21 – 2019-01-29 | fda.gov ↗ |
| Approved | US (FDA) | VFEND | — | 2002-05-24 | fda.gov ↗ |
| Approved | EU (EMA) | Vfend | — | 2002-03-19 | europa.eu ↗ |
Trials 99 · started per year
today
EU approved 2002
US approved 2002
3
1
2
1
2
7
1
5
4
3
8
6
3
4
2
3
4
5
4
1
8
3
5
4
4
1
2
2
19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04072640 | Jan 2021 → Jul 2022 | Cryptococcal meningitis, HIV infectious disease | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| Phase 126 trials · 1 met primary | ||||||
| Phase 1 | NCT07426042 | Apr → May 2026 overdue | — | Min Kyu Park | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07457203 | Apr → May 2026 overdue | — | Beijing Union Pharmaceutical Factory Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06493409 | Aug → Dec 2024 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05822544 | Apr 2023 → Feb 2026 overdue | obesity disorder, type 2 diabetes mellitus | OrsoBio, Inc | Recruiting | No outcome recorded |
| Phase 1 | NCT05458102 | Aug 2022 → May 2023 | HIV infectious disease | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1 | NCT05264142 | Apr 2022 → Mar 2023 | — | University Hospital, Geneva | Unknown | No outcome recorded |
| Phase 1 | NCT04865419 | Jun 2021 → Aug 2023 | hematopoietic and lymphoid cell neoplasm | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT04576325 | Nov 2020 → Nov 2021 | asthma | TFF Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04551963 | Nov 2020 → Feb 2022 | B-cell neoplasm | BeiGene | Completed | Mixed |
| Phase 1 | NCT05330000 | May → Jul 2020 | — | The Affiliated Hospital of Qingdao University | Completed | No outcome recorded |
| Phase 1 | NCT04229303 | Feb → Aug 2020 | allergic bronchopulmonary aspergillosis | Zambon SpA | Completed | No outcome recorded |
| Phase 1 | NCT04145583 | Dec 2019 → Jan 2020 | — | Sichuan Haisco Pharmaceutical Group Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04872231 | Nov 2019 → Jul 2020 | — | TFF Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03760276 | Aug → Oct 2018 | fungal infectious disease | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT03515382 | Mar → Jun 2018 | — | Lakefront Biotherapeutics NV | Completed | No outcome recorded |
| Phase 1 | NCT02906176 | Sep → Nov 2016 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02631954 | Sep → Oct 2015 | aspergillosis, candidiasis | Chong Kun Dang Pharmaceutical | Completed | Met primary |
| Phase 1 | NCT02381080 | May 2015 → Jun 2016 | B-cell chronic lymphocytic leukemia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02227797 | Jan 2015 → Sep 2017 | fungal infectious disease | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT01950507 | Feb 2014 → May 2018 | graft versus host disease | National Institutes of Health Clinical Center (CC) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01787032 | Jan → Apr 2013 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01657201 | Sep → Nov 2012 | systemic mycosis | Samyang Biopharmaceuticals Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00855101 | Apr → Jul 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00792246 | Dec 2008 → Jul 2012 | graft versus host disease | Phillip Brian Smith | Completed | No outcome recorded |
| Phase 1 | NCT00136968 | Apr → May 2005 | fungal infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00005912 | Jun 2000 → Jan 2001 | aspergillosis, candidiasis | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02014558 | Oct 2013 → Aug 2017 | acute myeloid leukemia | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00150319 | Jun → Oct 2005 | kidney failure | Pfizer | Terminated | No outcome recorded |
| Phase 1/2 | NCT00174473 | Jun 2003 → Aug 2005 | neutropenia | Pfizer | Completed | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT03672292 | Jan 2019 → Mar 2023 | invasive aspergillosis | Scynexis, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02689713 | Jun → Nov 2018 | — | Kenneth Hargreaves | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03327727 | Feb 2018 → Jan 2019 | invasive aspergillosis | Vical | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04110860 | Feb → Jun 2018 | pityriasis versicolor | Sara Botros | Completed | No outcome recorded |
| Phase 2 | NCT01887457 | Sep 2014 → Nov 2016 | aspergillosis, fusariosis, immunodeficiency disease | Brynn Chappell | Suspended | No outcome recorded |
| Phase 2 | NCT01576315 | Jun 2014 → Oct 2015 | aspergillosis, cystic fibrosis | Rennes University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01501708 | Dec 2011 → Jun 2017 | disease related to hematopoietic stem cell transplant, leukemia | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 2 | NCT01383993 | Sep 2011 → May 2013 | aspergillosis | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT02366884 | Jul 2011 → Dec 2022 | neoplasm | Dr. Frank Arguello Cancer Clinic | Unknown | No outcome recorded |
| Phase 2 | NCT00739934 | Dec 2008 → Oct 2009 | candidemia | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00556998 | Jun 2008 → Dec 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00418951 | Nov 2006 → Oct 2009 | acute myeloid leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00059878 | Aug 2003 → Jan 2005 | cancer of unknown primary site, infectious disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00238355 | Aug 2003 → Jun 2008 | cancer of unknown primary site, infectious disease | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00066599 | Jun 2003 → Jun 2004 | kidney cancer, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm +4 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/33 trials · 1 missed | ||||||
| Phase 2/3 | NCT03230058 | Jan 2017 → Mar 2018 | fungal infectious disease | L.V. Prasad Eye Institute | Unknown | Missed primary |
| Phase 2/3 | NCT01621321 | Jun 2013 → Apr 2016 | allergic bronchopulmonary aspergillosis | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 2/3 | NCT00159822 | Jul 2005 → Dec 2008 | aspergillosis | Pfizer | Completed | No outcome recorded |
| Phase 320 trials · 1 met primary · 6 missed | ||||||
| Phase 3 | NCT05708625 | Jan 2022 → Dec 2023 | cutaneous leishmaniasis | Zagazig University | Unknown | No outcome recorded |
| Phase 3 | NCT04824417 | Mar 2021 → May 2024 | aspergillosis | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | Missed primary |
| Phase 3 | NCT02731638 | Sep 2016 → Jul 2018 | corneal ulcer, fungal keratitis | University of California, San Francisco | Completed | Missed primary |
| Phase 3 | NCT01092832 | Oct 2010 → May 2013 | candidiasis | Pfizer | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00996736 | Apr 2010 → Jul 2012 | corneal ulcer, fungal keratitis | University of California, San Francisco | Completed | Met primary |
| Phase 3 | NCT00836875 | May 2009 → May 2013 | invasive aspergillosis | Pfizer | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00904995 | May 2009 → Jul 2010 | fungal infectious disease, leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00893555 | Apr 2009 → Nov 2016 | fungal infectious disease, hematopoietic and lymphoid cell neoplasm | Jan-Willem C Alffenaar | Completed | Missed primary |
| Phase 3 | NCT00531479 | Jul 2008 → Apr 2011 | aspergillosis | Pfizer | Completed | Missed primary |
| Phase 3 | NCT00289991 | Mar 2006 → Feb 2009 | opportunistic mycosis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00150345 | Jan 2005 → Apr 2009 | fungal infectious disease | Pfizer | Completed | Missed primary |
| Phase 3 | NCT00152594 | Oct 2004 → Jan 2006 | acute myeloid leukemia | University of Cologne | Terminated | No outcome recorded |
| Phase 3 | NCT00075803 | Nov 2003 → Sep 2006 | infectious disease, leukemia, lymphoma | Medical College of Wisconsin | Completed | Missed primary |
| Phase 3 | NCT00015665 | Apr 2001 → Mar 2003 | fungal infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00001940 | Dec 1999 → Jul 2001 | fungal infectious disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00001810 | Apr 1999 → Oct 2000 | aspergillosis, candidiasis | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00163111 | Sep 1998 → May 2003 | candidemia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00001757 | Nov 1997 → Jul 2000 | fungal infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00001646 | Aug 1997 → Aug 2000 | AIDS, aspergillosis, neutropenia | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00003031 | Jun 1997 → Oct 2000 | infectious disease | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 420 trials | ||||||
| Phase 4 | NCT06582186 | Oct 2024 → Oct 2027 expected | hematopoietic and lymphoid cell neoplasm, invasive aspergillosis | University Hospital, Grenoble | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04238884 | Jan 2020 | fungal infectious disease | Instituto de Investigación Hospital Universitario La Paz | Unknown | No outcome recorded |
| Phase 4 | NCT05380245 | Nov 2018 | — | Abdul Wali Khan University Mardan | Completed | No outcome recorded |
| Phase 4 | NCT03731169 | Jan 2018 → Aug 2019 | invasive aspergillosis | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 4 | NCT02912156 | Jun → Jul 2016 | fungal infectious disease | Yung Shin Pharm. Ind. Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02576366 | Jun 2016 → May 2017 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT02283905 | Jun 2015 → Sep 2020 | blastomycosis | University of Manitoba | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02234739 | Oct 2014 → Oct 2016 | chronic obstructive pulmonary disease, invasive aspergillosis | Red Cross Hospital, Hangzhou, China | Unknown | No outcome recorded |
| Phase 4 | NCT01416025 | Jan 2012 → Dec 2014 | fungal infectious disease | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT01030653 | Nov 2009 → Apr 2010 | — | Manjunath Prakash Pai | Completed | No outcome recorded |
| Phase 4 | NCT01539330 | Feb 2009 → Feb 2013 | — | Martin-Luther-University Halle-Wittenberg | Completed | No outcome recorded |
| Phase 4 | NCT00940017 | Sep → Oct 2008 | aspergillosis, candidemia | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00620074 | Aug 2008 → Feb 2009 | invasive aspergillosis | Pfizer | Terminated | No outcome recorded |
| Phase 4 | NCT00455364 | Apr 2007 | infectious disease | University of Chicago | Terminated | No outcome recorded Stop: Business |
| Phase 4 | NCT00300677 | Mar 2007 → Aug 2008 | fungal infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00423163 | Feb 2007 → ? | invasive aspergillosis | Astellas Pharma Inc | Withdrawn | No outcome recorded |
| Phase 4 | NCT00386802 | Aug 2006 → Dec 2008 | fungal infectious disease | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00288197 | Jan 2006 → Jun 2007 | fungal infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00143312 | Feb 2005 → Apr 2008 | fungal infectious disease | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00647907 | Apr 2003 → May 2004 | aspergillosis, candidiasis, cryptococcosis | Pfizer | Completed | No outcome recorded |
| Phase not applicable10 trials · 1 met primary | ||||||
| — | NCT06710600 | Sep 2022 → Apr 2024 | photosensitivity disease | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT07816510 | Mar → Aug 2021 | dermatophytosis | Chittagong Medical College | Completed | No outcome recorded |
| — | NCT03827278 | Dec 2018 → Dec 2021 | penicilliosis | Guangxi Medical University | Unknown | Met primary |
| — | NCT02396225 | Mar 2015 → Dec 2016 | invasive aspergillosis | University of Aarhus | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01344512 | Jun 2011 → Sep 2014 | — | University Hospital, Bordeaux | Completed | No outcome recorded |
| — | NCT01104376 | Mar 2010 → Apr 2011 | efavirenz toxicity | Indiana University | Completed | No outcome recorded |
| — | NCT00890708 | Nov 2008 → Dec 2011 | fungal infectious disease | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT02714504 | Aug 2008 → Dec 2014 | fusariosis, tinea unguium | Federal University of Rio de Janeiro | Completed | No outcome recorded |
| — | NCT00079222 | Nov 2003 → Apr 2005 | cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| — | NCT00023530 | Sep 2001 → Aug 2006 | graft versus host disease, leukemia, myelodysplastic syndrome, plasma cell myeloma | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05897294 | — | allergic bronchopulmonary aspergillosis, invasive aspergillosis | TFF Pharmaceuticals, Inc. | No longer available | No outcome recorded |
| Comparator or background therapy31 trials | ||||||
| Phase 0 | NCT05528354 Background | Jun 2022 → Dec 2025 | disease related to hematopoietic stem cell transplant | Zhejiang University | Unknown | No outcome recorded |
| Phase 0 | NCT05268718 Comparator | Aug 2021 → Dec 2023 | corneal ulcer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT06616168 Background | Sep 2023 → Aug 2026 overdue | bacterial vaginosis | Danylo Halytsky Lviv National Medical University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT00833482 Comparator | Sep 2009 → Jul 2010 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01080651 Comparator | Dec 2008 → Mar 2009 | invasive aspergillosis | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00942773 Comparator | Dec 2008 → Mar 2009 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00353158 Comparator | May 2007 → Sep 2011 | bacterial infectious disease, fungal infectious disease | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | No outcome recorded |
| Phase 1/2 | NCT04988555 Background | Feb 2022 → Jun 2027 expected | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma | Sumitomo Pharma America, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT00557362 Comparator | Nov 2007 → Aug 2008 | fungal keratitis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT07215273 Comparator | Feb → Dec 2026 expected | fungal infectious disease | Elion Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06680544 Comparator | Nov 2024 → Mar 2025 overdue | dermatophytosis | Sheikh Zayed Medical College | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04294641 Background | May 2021 → Jun 2024 | chronic graft versus host disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01207128 Comparator | Feb 2011 → Jan 2012 | invasive aspergillosis | University of Arkansas | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT03799809 Comparator | Dec 2016 → Dec 2018 | pulmonary aspergilloma | All India Institute of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT06774144 Comparator | Oct 2025 → Dec 2028 expected | fungal infectious disease | Fernanda P Silveira, MD, MS | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT04876716 Background | May 2021 → May 2024 | invasive aspergillosis | Erasmus Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT03471988 Comparator | Apr 2018 → Apr 2021 | systemic mycosis | Asahi Kasei Therapeutics Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02180165 Comparator | Jul 2014 → Jan 2018 | aspergillosis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01503515 Comparator | Mar 2013 → Dec 2019 | fungal infectious disease, hematopoietic and lymphoid cell neoplasm | Children's Oncology Group | Completed | Missed primary |
| Phase 3 | NCT01188759 Comparator | May 2012 → Aug 2014 | invasive aspergillosis, neuroaspergillosis | Pfizer | Withdrawn | No outcome recorded |
| Phase 3 | NCT00997035 Comparator | May 2010 → Jan 2016 | corneal ulcer, fungal infection of eye | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT00689338 Background | Jul 2008 → May 2010 | candidiasis, invasive | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00624143 Comparator | Feb 2008 → Dec 2009 | acute leukemia | All India Institute of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT00413218 Comparator | Mar 2007 → Mar 2015 | candidemia | Astellas Pharma Inc | Completed | Missed primary |
| Phase 3 | NCT00412893 Comparator | Mar 2007 → Mar 2013 | invasive aspergillosis | Astellas Pharma Inc | Completed | Met primary |
| Phase 4 | NCT07072923 Comparator | Sep 2025 → Jul 2027 expected | osteomyelitis | University of Arizona | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT00548262 Background | Feb 2008 → Oct 2009 | candidemia | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00496197 Background | Jul 2007 → Jun 2010 | candidiasis | Pfizer | Completed | No outcome recorded |
| — | NCT07244367 Comparator | Sep 2025 → Sep 2026 overdue | acute myeloid leukemia | Sohag University | Recruiting | No outcome recorded |
| — | NCT03138785 Background | Jan 2015 → Jun 2017 | — | Farabi Eye Hospital | Unknown | No outcome recorded |
| — | NCT02328053 Background | Feb 2014 → Jul 2015 | mycotic corneal ulcer | Aravind Eye Care System | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2020-07-20 | Yung Shin Pharm. Ind. Co., Ltd. | Regulatory 感染疾病日益複雜 永信聚焦發展重症感染藥物 com.tw ↗
以原料藥垂直整合藥品策略，成功開發triazole 類第二代廣效性抗黴菌藥物-Voriconazole，具有錠劑及注射劑兩種規格可提供轉換治療，目前已取得台灣與日本上市許可，未來將持續佈局歐、美等高法規市場。 |
| 2018-07-18 | Zydus Lifesciences Limited | Regulatory Zydus receives four consecutive ANDA approvals from the USFDA zyduslife.com ↗
Zydus Cadila announced that it has received four consecutive final approvals from the USFDA to market Olanzapine Tablets USP, Glipizide Extended -Release Tablets, Voriconazole for Injection and Fluocinonide Topical Solution USP. |
| 2016-06-06 | Lupin Limited | Regulatory Lupin Receives FDA Approvals for Generic Vfend® Tablets 50mg, 200mg & Vfend® Oral Suspension, 40 mg/mL lupin.com ↗
has received final approvals for its Voriconazole® Tablets, 50 mg & 200 mg and Voriconazole® Oral Suspension, 40 mg/mL from the United States Food and Drug Administration (FDA) |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-07-20 | Yung Shin Pharm. Ind. Co., Ltd. | 感染疾病日益複雜 永信聚焦發展重症感染藥物 com.tw ↗ |
| 2018-07-18 | Zydus Lifesciences Limited | Zydus receives four consecutive ANDA approvals from the USFDA zyduslife.com ↗ |
| 2016-12-18 | Lupin Limited | Lupin Launches Generic Vfend® Tablets and Vfend® Oral Suspension in the US lupin.com ↗ |
| 2016-06-06 | Lupin Limited | Lupin Receives FDA Approvals for Generic Vfend® Tablets 50mg, 200mg & Vfend® Oral Suspension, 40 mg/mL lupin.com ↗ |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 133 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Voriconazole | “Calcium sulfate beads will be loaded with best available antibiotics based on surgeon/infectious disease specialist determination from the following options (vancomycin,...” NCT07072923 ↗127“Group C (TV group) receiving Oral Terbinafine (250 mg once daily) combined with Voriconazole, dosed according to body weight at or over 40 kg body weight: 200 mg twice daily...” NCT07816510 ↗ “Voriconazole or isavuconazole or posaconazole will be dosed according to the SPC and according to the route of administration (IV or orally) that is preferred by the treating physician.” NCT04876716 ↗ “This is a study to investigate the pharmacokinetics, safety and tolerability of intravenous voriconazole and SBECD in patients with moderate renal insufficiency” NCT00150319 ↗ “To assess the pharmacokinetics (PK) of voriconazole and anidulafungin in patients with invasive aspergillosis (IA) in comparison with other populations” PMID 24913161 ↗ Jun 2014 “This is a study to investigate the safety and efficacy of voriconazole for the treatment of candidemia in critically ill non-neutropenic patients” NCT00163111 ↗ “Triazoles (Fluconazole, Itraconazole, Voriconazole), Imidazoles (Ketoconazole), Nystatin and Amphotericin B are used the most” NCT06616168 ↗ “topical antifungal medications like natamycin eye drops and voriconazole eye drops” NCT02328053 ↗ “Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole” NCT02366884 ↗ “if Voriconazole or Posaconazole is used to prevent or treat fungal infections” NCT05528354 ↗ “Voriconazole dose will be adjusted based on per protocol obtained TDM levels” NCT01416025 ↗ |
| Known as | NSC-759888 | ChEMBL registry synonym — accepted as the source's own label CHEMBL638 ↗ |
| Known as | UK-109,496 | ChEMBL registry synonym — accepted as the source's own label CHEMBL638 ↗ |
| Known as | Vaway FC Tablets | “Vaway FC Tablets 200mg (Voriconazole)” NCT02912156 ↗ |
| Known as | vfend | “The purpose of this study was to evaluate the pharmacokinetic equivalency of a test formulation and reference formulation (Vfend®) of Voriconazole.” PMID 36869387 ↗ Mar 20237“Study to Evaluate the Pharmacokinetic Properties of SYP-1018 (Voriconazole-loaded PNP) and Voriconazole (Vfend)” NCT01657201 ↗ “To be determined mg of Voriconazole (Vfend®, anti-fungal agent)” NCT03760276 ↗ “Vfend (voriconazole) intravenous infusion” NCT02906176 ↗ “Antifungal drug. VORICONAZOL. (VFEND®)” NCT00386802 ↗ “Drug: Vfend (voriconazole)” NCT00496197 ↗ “Drug: voriconazole (Vfend)” NCT00150345 ↗ |
| Known as | VFEND FC Tablets | “VFEND FC Tablets 200mg (Voriconazole)” NCT02912156 ↗ |
| Known as | VFEND I.V. | “Voriconazole (VFEND® I.V., Pfizer, New York, NY) will be prepared as a 1% solution.” NCT00557362 ↗ |
| Known as | VFend(R) | “To evaluate the efficacy of voriconazole (VFend(R)) as first line treatment for proven chronic bronchopulmonary aspergillosis, in minimally immunocompromised or...” NCT00159822 ↗ |
| Known as | Vori | “Voriconazole (Vori) 6mg/kg BID IV loading dose on Day 1 followed by 4mg/kg IV BID thereafter.” NCT07215273 ↗ |
| Known as | VORICONAZOL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00386802 ↗ |
| Known as | Voriconazol Aristo | “voriconazole (Voriconazol Aristo®) 200mg” NCT06710600 ↗ |
| Known as | Voriconazole accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL638 ↗ |
| Known as | Voriconazole hikma (previously voriconazole hospira) | ChEMBL registry synonym — accepted as the source's own label CHEMBL638 ↗ |
| Action | Inhibit | “Voriconazole inhibits an essential step of the biosynthesis of an important component of the fungal cell wall (ergosterol).” NCT00418951 ↗ |
| Modality | Small molecule | “Voriconazole is a new triazole that has shown in phase II studies to be very active against Aspergillus sp.” NCT00015665 ↗ |
| Route | Intravenous | “available in an intravenous and oral formulation” NCT00001646 ↗ |
| Route | Oral | “available in an intravenous and oral formulation” NCT00001646 ↗ |
| Target | CYP2B6 | “Efavirenz, a nonnucleoside HIV-1 reverse transcriptase inhibitor, is mainly cleared by CYP2B6, an enzyme strongly inhibited in vitro by voriconazole.” PMID 27600044 ↗ Oct 2016 |